Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth's Tygacil Gains New Indication | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Wyeth’s Tygacil Gains New Indication

Wyeth Pharmaceuticals received approval from the FDA for Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth Pharmaceuticals received approval from the FDA for Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. The drug was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults. CABP infects an estimated 4.5 million people each year.

“The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed,” says Joseph Camardo, M.D., senior vice president, Global Medical Affairs, Wyeth Pharmaceuticals. “The approval of Tygacil for CABP is an important milestone in Wyeth’s commitment to exploring new treatment options in the anti-infective therapeutic area.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters